Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: A study of 74 cases

British Journal of Cancer

Volumn 73, Issue 6, 1996, Pages 735-743

  Soubeyran, I ^a   Quenel N ^a   Mauriac, L ^a   Durand, M ^a   Bonichon, F ^a   Coindre, J M ^a,b  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Breast carcinomas; C erbB 2; GST ; Hormonal receptors; pS2; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; HORMONE RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CELL SELECTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0029978288     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.129     Document Type: Article

References (52)

1. ALLEGRA JC, BARLOCK A, HUFF KK AND LIPPMAN ME. (1980). Changes in multiple or sequential oestrogen receptor determinations in breast cancer. Cancer, 45, 792-794.
2. BERRY M, METZGER D AND CHAMBON P. (1990). Role of two activating domains of the estrogen receptor in cell-type and promoter context-dependent agonistic activity of the antioestrogen 4-hydroxylamoxifen. EMBO J., 9, 2811-2818.
3. BRUNNER N, BOULAY V, FOJO A, FRETER CE, LIPPMAN ME AND CLARKE R. (1993). Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of oestrogen-regulated genes but without detectable DNA amplifications. Cancer Res., 53, 283-290.
4. CHALBOS D, PHILIPS A, GALTIER F AND ROCHEFORTH H. (1993). Synthetic antioestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3′, 5′-monophosphate in MCF-7 cells. Endocrinology, 133, 571-576.
5. DALY RJ AND DARBRE PD. (1990). Cellular and molecular events in loss of oestrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res., 50, 5868-5875.
6. DATI C, ANTONIOTTI S, TAVERNA D, PERROTEAU I AND DE BORTOLI M. (1990). Inhibition of c-erbB-2-oncogene expression by oestrogens in human breast cancer cells. Oncogene, 5, 1001-1006.
7. DORION-BONNET F, QUENEL N, COINDRE JM, MAURIAC L, BONICHON F, DURAND M, WAFFLARD J, MOSCOW JA, COWAN KH AND GUALDE N. (1993). Expression of the GSTπ gene and response to tamoxifen therapy in locally advanced breast carcinomas. Ann. NY Acad. Sci., 68, 182-185.
8. EARLY BREAST CANCER TRIALISTS COLLABORATIVE GROUP. (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet, 339, 1-15, 71-85.
9. FRIGO B, PILOTTI S, ZURRIDA S, ERMELLINO L, MANZARI A AND RILKE F. (1995). Analysis of estorgen and progesterone receptors on preoperative fine-needle aspirates. Breast Cancer Res. Treat., 33, 179-184.
10. GILBERT L, ELWOOD LJ, MERINO M, MASOOD S, BARNES R, STEINBERG SM, LAZAROUS DF, PIERCE L, D'ANGELO T, MOSCOW JA, TOWNSEND AJ AND COWAN KH. (1993). A pilot study of Pi-class glutathione S-transferase expression in breast cancer: coirelation with oestrogen receptor expression and prognosis in node-negative breast cancer. J. Clin. Oncol., 11, 49-58.
11. GOTTARDIS MM, ROBINSON SP, SATYASWAROOP PG AND JORDAN VG. (1988). Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48, 812-815.
12. HALACHMI S, MARDEN E, MARTIN G, MACKAY H, ABBONDANZA C AND BROWN M. (1994). Oestrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science, 264, 1455-1458.
13. HENRY JA, NICHOLSON S, HENNESY C, LENNARD TWJ, MAY FEB AND WESTLEY BR. (1989). Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br. J. Cancer, 61, 32-38.
14. HENRY JA, PIGGOTT NH, MALLICK UK, NICHOLSON S, FARNDON JR, WESTLEY BR AND MAY FEB. (1991). pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br. J. Cancer., 63, 615-622.
15. HOLDAWAY IM, FRACP MD AND BOWDITCH JV (1983). Variation in receptor status between primary and metastatic breast cancer. Cancer, 52, 479-485.
16. HORWITZ KB, KOSEKI Y AND MCGUIRE WL. (1978). Oestrogen control of progesterone receptor in human breast cancer: role of estradiol and antioestrogen. Endocrinology, 103, 1742-1751.
17. HOWIE AF, MILLER WR, HAWKINS RA, HUTCHINSON AR AND BECKETT GJ. (1989). Expression of glutathione S-transferase B1, B2, Mu and Pi in breast cancers and their relationship to oestrogen receptor status. Br. J. Cancer, 60, 834-837.
18. HULL III DF, CLARK GM, OSBORNE K, CHAMNESS C, KNIGHT III WA AND MCGUIRE WL. (1983). Multiple oestrogen receptor assays in human breast cancer. Cancer Res., 43, 413-416.
19. HURLIMANN J, GEBHARD S AND GOMEZ F. (1993). Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology, 23, 239-248.
20. JAKOWLEW SB, BREATHNACH R, JELTSCH JM, MASIAKOWSKI P AND CHAMBON P. (1984). Sequence of the pS2 mRNA induced by oestrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res., 12, 2861-2878.
21. KATZ RL, PATEL S, SNEIGE N, PRITSCHE Jr, HORTOBAGYI GN, AMES FC, BROOKS T AND ORDONEZ NG. (1990). Comparison of immunocytochemical and biochemical assays for oestrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res. Treat., 15, 191-203.
22. KATZENELLENBOGEN BS, MILLER MA, MULLICK A AND SHEEN YY. (1985). Antioestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with oestrogen receptors and additional antioestrogen binding sites. Breast Cancer Res. Treat., 5, 231-243.
23. KIDA N, YOSHIMURA T, MORI K AND HAYASHI K. (1989). Hormonal regulation of synthesis and secretion of pS2 protein relevant growth of human breast cancer cells (MCF-7). Cancer Res., 49, 3494-3498.
24. LE ROY X, EXCOT C, BROUILLET JP, THEILLET C, MAUDELONDE T, SIMONY-LAFONTAINE J, PUJOL H AND ROCHEFORT H. (1991). Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene, 6, 431-437.
25. LIPPMAN ME, DICKSON RB, BATES S, KNABBE C, HUFF K, SWAIN S, MCMANAWAY M, BRONZERT D, KASID A AND GELMANN EP. (1986). Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res. Treat., 7, 59-70.
26. de MASCAREL I, SOUBEYRAN I, MAC GROGAN G, WAFFLART J, BONICHON F, DURAND M, AVRIL A, MAURIAC L, TROJANI M AND COINDRE JM. (1996). Immunohistochemical analysis of oestrogen receptors in 938 breast carcinomas: concordance with biochemical assay and prognostic significance. App. Immunohistochem. In press.
27. MASIAKOWSKI P, BREATHNACH R, BLOCH J, GANNON R, KRUST A AND CHAMBON P. (1982). Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res., 10, 7895-7903.
28. MAURIAC L, WAFFLART J, DURAND M, PARSI B, de MASCAREL I, TROJANI M AND MEUGE-MORAW C. (1981). Contribution of drill-biopsies to pre-treatment investigation of breast adenocarcinomas. Bull. Cancer., 68, 417-421.
29. MAY E, MOURIESSE H, MAY-LEVIN F, QIAN JF, MAY P AND DELARUE JC. (1990). Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br. J. Cancer. 62, 430-435.
30. MELCHOR JC, RODRIGUEZ-ESCUDERO FJ, LUJAN S AND CORCOSTEGUI B. (1990). Variation of oestrogen and progesterone receptor status in breast cancer after tamoxifen therapy. Oncology, 47, 467-470.
31. MORROW CS, CHIU J AND COWAN KH. (1992). Posttranscriptional control of glutathione S-transferase π gene expression in human breast cancer cells. J. Biol. Chem., 267, 10544-10550.
32. MOSCOW JA, TOWNSEND AJ AND GOLDSMITH ME. et al. (1988). Isolation of the human anionic glutathione-S-transferase gene and the relation of its expression to oestrogen receptor content in primary breast cancer. Proc. Natl. Acad. Sci., 85, 6518-6522.
33. NICHOLSON RI, MCCLELLAND RA, FINLAY P, EATON CL, GULLICK WJ, DIXON AR, ROBERTSON JFR, ELLIS IO AND BLAMEY RW. (1993). Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur. J. Cancer., 29A, 1018-1023.
34. NOGUCHI M, TAJIRI K, TANIYA T, KUMAKI T, ASHIKARI A AND MIYAZAKI I. (1990). Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7). Oncology, 47, 19-24.
35. QUÉNEL N, COINDRE JM, WAFFLART J, BONICHON F, de MASCAREL I, TROJANI M, DURAND M AND AVRIL A. (1995). The prognostic value of c-erbB-2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res. Treat., 35, 283-291.
36. READ LD, KEITH D, SLAMON DJ AND KATZELLENBOGEN BS. (1990). Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res., 50, 3947-3951.
37. RILKE F, COLNAGHI MI, CASCINELLI N, ANDREOLA S, BALDINI MT, BUFALINO R, DELLA PORTA G, MENARD S, PIEROTTI MA AND TESTORI A. (1991). Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int. J. Cancer, 49, 44-49.
38. RIO MC, BELLOCQ JP, DANIEL JY, TOMASSETTO C, LATHE R, CHENARD MP, BATZENSCHLAGER A AND CHAMBON P. (1988). Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science, 241, 705-708.
39. ROCHEFORT H. (1991). Mechanism of action of high-affinity antioestrogens. Am. J. Clin. Oncol., 14, S1-S4.
40. SCHWARTZ LH, KOERNER FC, EDGERTON SM, SAWICKA JM, RIO MC, BELLOCQ JP, CHAMBON P AND THOR AD. (1991). pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res., 51, 624-628.
41. SOUBEYRAN I, COINDRE JM, WAFFLART J, BONICHON F, de MASCAREL I, TROJANI M, DURAND M AND AVRIL A. (1995). Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res. Treat., 34, 119-128.
42. SOUBEYRAN I, QUENEL N, COINDRE JM, BONICHON F, DURAND M, WAFFLART J AND MAURIAC L. PS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Submitted to Br. J. Cancer.
43. SUTHERLAND RL, GREEN MD, HALL RE, REDDEL RR AND TAYLOR IW. (1983). Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the G0-G1 phase of the cell cycle. Eur. J. Cancer Clin. Oncol., 19, 615-621.
44. TAYLOR RE, POWLES TJ, HUMPHREYS, J, BETTELHEIM R, DOWSETT M, CASEY AJ, NEVILLE AM AND COOMBES RC. (1982). Effects of endocrine therapy on steroid-receptor content of breast cancer. Br. J. Cancer, 45, 80-85.
45. TOIKKANEN S, HELIN H, ISOLA J AND JOENSUU H. (1992). Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J. Clin. Oncol., 10, 1044-1048.
46. TSUDA H, HIROHASHI S, SHIMOSATO Y, HIROTA T, TSUGANE S, WATANABE S, TERADA M AND YAMAMOTO H. (1990). Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer, 65, 1794-1800.
47. VERING A, VOCKEL A, STEGMÜLLER M AND BENDER HG. (1993). Immunobiochemical assay for determination of nuclear steroid receptors during tamoxifen therapy. J. Cancer Res. Clin. Oncol., 119, 415-420.
48. WÄRRI AM, LAINE AM, MAJASUO KE, ALITALO KK AND HÄRKÖNEN PL. (1991). Oestrogen suppression of erbB-2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int. J. Cancer, 49, 616-623.
49. WÄRRI AM, HUOVINEN RL, LAINE AM, MARTIKAINEN PM AND HÄRKÖNEN PL. (1993). Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J. Natl. Cancer Inst., 85, 1412-1418.
50. WASEDA N, KATO Y, IMURA H AND KURATA M. (1981). Effects of tamoxifen on oestrogen and progesterone receptos in human breast cancer. Cancer Res., 41, 1984-1988.
51. WILSON YG, RHODES M, IBRAHIM NBN, PADFIELD CJH AND CAWTHORN SJ. (1994). Immunocytochemical staining of pS2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br. J. Surg., 81, 1155-1158.
52. WRIGHT C, NICHOLSON S, ANGUS B, SAINSBURY JRC, FARNDON J, CAIRNS J, HARRIS AL AND HORNE CHW. (1992). Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer., 65, 118-121.